KDR

(redirected from VEGFR2)
Also found in: Acronyms.

KDR

A gene on chromosome 4q11-q12 that encodes a vascular endothelial growth factor receptor known as kinase insert domain receptor, which is a type-III receptor tyrosine kinase. KDR is the main mediator of VEGF-induced endothelial proliferation, survival, migration, tubular morphogenesis and sprouting.

Molecular pathology
KDR mutations have been linked to infantile capillary haemangiomas.
Mentioned in ?
References in periodicals archive ?
Cuantificacion de la expresion de VEGFR2. El efecto del tratamiento con AS y AAS sobre los fetos de pollo en la expresion de VEGFR2 se muestra en la Figura 3.
VEGF and VEGFR2 activities were present in the dentine-pulp complex of immature and mature teeth.
Band densities were tested with antibodies against FMOD (1: 200, sc-33772; Santa Cruz Biotechnology, Inc.), VEGF (1:200, ab46154; Abcam, Cambridge, MA, USA), VEGFR2 (1:1000, #55B11; Cell Signaling Technology (CST), Danvers, MA, USA), phosphoinositide 3 kinase (PI3K/AKT) (1: 1000, #4685; CST), phosphorylated AKT (p-AKT) (1: 1000, #4060; CST), ERK1/2 (1: 1000, #9102; CST), and phosphorylated ERK1/2 (p-ERK1/2) (1:1000, #4370; CST), followed by incubation with a horseradish peroxidase (HRP)-conjugated goat antibody against rabbit IgG (1: 1000, #7074; CST).
targeted both VEGF and VEGFR2 with their cRGD micelle-siRNA particle, which was stabilized with 2-iminothiolane; compared to untreated tumors, these particles reduced tumor growth by more than 80% [27].
Hagikura et al., "The sphingosine-1phosphate receptor S1PR1 restricts sprouting angiogenesis by regulating the interplay between VE-cadherin and VEGFR2," Developmental Cell, vol.
Based on the expression ofVEGFr and PDGFr, a response to targeted tyrosine kinase inhibitor therapy with toceranib, a small molecule inhibitor of VEGFr2 and PDGFr[beta], was hypothesized.
VEGF Trap (aflibercept) not only binds multiple isoforms of VEGF-Abut also inhibits the activation of VEGFR1 and VEGFR2. VEGF Trap binds to VEGF-A faster and with higher affinity than bevacizumab and ranibizumab [6].
Zebrafish express two VEGFR2 homologs known as Kdr1/Flk1 and Kdr/Kdrb.
The growth factors upregulate miR-296 and this upregulation favours angiogenesis by reducing levels of hepatocyte growth factor-regulated tyrosine kinase substrate (HGS) through targeting HGS mRNA, which is responsible for degradation of angiogenic receptors such as VEGFR2 and PDGFRb in endothelial cells [163].
On stimulation with VEGF, it interacts with Vascular Endothelial Growth Factor Receptor 2 (VEGFR2) and forms a complex with VEGFR2.
After blocking, primary anti bodies raised against VEGFA (1:800, WL00009b, Wanleibio), VEGFR2 (1:300, sc-504; Santa Cruz Biotechnology Co., Ltd.), p-VEGFR2 (1:200 sc-16629-R Santa Cruz), Akt (1:500, 4691s; Santa Cruz), P-Akt (Ser473, 1:500, 4060 s; Cell Signaling Technology, USA), HIF-1[alpha] (1:800, 209601-AP; ProteinTech Group), [beta]-actin (1:5000, BM0005; Boster, China), p-I[kappa]B[alpha] (1:1000; 2859, Cell Signaling Technology), and I[kappa]B[alpha] (1:1000, 9242; Cell Signaling Technology) were added, respectively, for overnight incubation at 4[degrees]C.